(2R)-4-[6,7-dimethyl-4-[3-(trifluoromethyl)cyclobutyl]pteridin-2-yl]-2-(6-methylpyridazin-4-yl)morpholine
C22H24F3N7O — CID 157044389
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2R)-4-[6,7-dimethyl-4-[3-(trifluoromethyl)cyclobutyl]pteridin-2-yl]-2-(6-methylpyridazin-4-yl)morpholine
(2R)-4-[6,7-dimethyl-4-[3-(trifluoromethyl)cyclobutyl]pteridin-2-yl]-2-(6-methylpyridazin-4-yl)morpholine (PubChem CID 157044389) has the molecular formula C22H24F3N7O and a molecular weight of 459.48 g/mol. Its IUPAC name is (2R)-4-[6,7-dimethyl-4-[3-(trifluoromethyl)cyclobutyl]pteridin-2-yl]-2-(6-methylpyridazin-4-yl)morpholine.
Molecular Properties
| Compound Name | (2R)-4-[6,7-dimethyl-4-[3-(trifluoromethyl)cyclobutyl]pteridin-2-yl]-2-(6-methylpyridazin-4-yl)morpholine |
|---|---|
| PubChem CID | 157044389 |
| Molecular Formula | C22H24F3N7O |
| Molecular Weight | 459.48 g/mol |
| Exact Mass | 459.20 |
| IUPAC Name | (2R)-4-[6,7-dimethyl-4-[3-(trifluoromethyl)cyclobutyl]pteridin-2-yl]-2-(6-methylpyridazin-4-yl)morpholine |
| SMILES | Cc1cc([C@@H]2CN(c3nc(C4CC(C(F)(F)F)C4)c4nc(C)c(C)nc4n3)CCO2)cnn1 |
| InChI | InChI=1S/C22H24F3N7O/c1-11-6-15(9-26-31-11)17-10-32(4-5-33-17)21-29-18(14-7-16(8-14)22(23,24)25)19-20(30-21)28-13(3)12(2)27-19/h6,9,14,16-17H,4-5,7-8,10H2,1-3H3/t14?,16?,17-/m0/s1 |
| InChIKey | QAHPHGHYRGEZSF-PREGVCBESA-N |
| XLogP | 3.77 |
| TPSA | 89.81 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 459.48 |
| LogP ≤ 5 | 3.77 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 157044389 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.